Publications
292
Citations
4,688
Est. group size
~3
Recurring co-author estimate
Active years
37
Publishing since 1990
Stephen L. Lessnick's research focuses on Ewing sarcoma, a rare bone and soft-tissue cancer that primarily affects children and young adults. His work centers on the fusion protein EWSR1::FLI1 (also called EWS/FLI), an abnormal protein created by a genetic rearrangement that drives this cancer, studying how it binds DNA, regulates genes, and interacts with other proteins to promote tumor growth. This research combines molecular and genomic laboratory studies with involvement in clinical trials testing new treatments for the disease.
Publication counts were fairly steady at modest levels through 2022, spiked sharply in 2023 (largely due to a cluster of supplementary materials tied to specific papers), then dropped off in 2024-2026, suggesting an irregular rather than steadily growing output.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- The DBD-α4 helix of EWSR1::FLI1 is required for GGAA microsatellite binding that underlies genome regulation in Ewing sarcoma
eLife · 2026
- The DBD-α4 helix of EWSR1::FLI1 is required for GGAA microsatellite binding that underlies genome regulation in Ewing sarcoma
eLife · 2024
- The DBD-α4 helix of EWS::FLI is required for GGAA microsatellite binding that underlies genome regulation in Ewing sarcoma
eLife · 2024
- The DBD-α4 helix of EWSR1::FLI1 is required for GGAA microsatellite binding that underlies genome regulation in Ewing sarcoma
eLife · 2024
- Author response: The DBD-α4 helix of EWSR1::FLI1 is required for GGAA microsatellite binding that underlies genome regulation in Ewing sarcoma
2024
- Supplementary Data 3 from NR0B1 Is Required for the Oncogenic Phenotype Mediated by EWS/FLI in Ewing's Sarcoma
2023
- Randomized Phase III Trial of Ganitumab With Interval-Compressed Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma: A Report From the Children's Oncology Group
Journal of Clinical Oncology · 2023
- The ETS transcription factor ETV6 constrains the transcriptional activity of EWS–FLI to promote Ewing sarcoma
Nature Cell Biology · 2023
- Supplementary Figure 1 from EWS/FLI1 Regulates Tumor Angiogenesis in Ewing's Sarcoma via Suppression of Thrombospondins
2023
- Supplementary Figure Legends 1-4 from EWS/FLI1 Regulates Tumor Angiogenesis in Ewing's Sarcoma via Suppression of Thrombospondins
2023
- Supplementary Figure 2 from EWS/FLI1 Regulates Tumor Angiogenesis in Ewing's Sarcoma via Suppression of Thrombospondins
2023
- Data from EWS/FLI1 Regulates Tumor Angiogenesis in Ewing's Sarcoma via Suppression of Thrombospondins
2023
- Supplementary Figure 3 from EWS/FLI1 Regulates Tumor Angiogenesis in Ewing's Sarcoma via Suppression of Thrombospondins
2023
- Supplementary Figure Legends 1-4 from EWS/FLI1 Regulates Tumor Angiogenesis in Ewing's Sarcoma via Suppression of Thrombospondins
2023
- Supplementary Figure 2 from EWS/FLI1 Regulates Tumor Angiogenesis in Ewing's Sarcoma via Suppression of Thrombospondins
2023
- Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature×42
- Cancer Research×11
- Oncotarget×6
- bioRxiv (Cold Spring Harbor Laboratory)×6
- eLife×4
- Julia Selich‐Anderson
Medicine · The Ohio State University
- Marcus R. Breese
Medicine · Indiana University
- Lucia Casadei
Medicine · The Ohio State University
- Shriya Deshmukh
Medicine · The Ohio State University
- James Lin Chen
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile